Duchenne Muscular Dystrophy (DMD)

Duchenne muscular dystrophy is a genetic disorder in which alterations of a protein called dystrophin lead to progressive muscle degeneration and weakness.

Blog Post

Clinical Trial Alert: ReveraGen BioPharma Seeks Participants for a Phase 2b DMD Study

By MDA Staff | March 12, 2019
Blog Post

In Their Shoes: 65 Years of IAFF’s Fight for MDA

By Lindsey Baker | March 5, 2019
Blog Post

FDA Accepts Sarepta Therapeutics’ New Drug Application (NDA) for Golodirsen to Treat DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | March 1, 2019
Blog Post

MDA Releases New DMD Fact Sheet During Duchenne Muscular Dystrophy Awareness Week

By MDA Staff | February 13, 2019
Blog Post

Solid Biosciences Announces Preliminary Results of DMD Gene Therapy Trial

By Jeanene Swanson | February 8, 2019
Blog Post

Newborn Screening for DMD and BMD: MDA Needs Your Help

By MDA Staff | January 15, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Catabasis Seeks Participants for a Phase 3 DMD Study

By MDA Staff | January 10, 2019
Blog Post

Wave Life Sciences Announces Phase 2/3 Duchenne Muscular Dystrophy Clinical Trial of Suvodirsen (WVE-210201) Selected for FDA Complex Innovative Trial Designs Pilot Program

By Jeanene Swanson | January 8, 2019
Featured Article

504 Plans What Parents Should Know

By MDA Staff | March 31, 2009